aspirin has been researched along with No-Reflow Phenomenon in 4 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with STEMI undergoing PPCI within 12hours of symptoms onset were included prospectively." | 1.46 | Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Aitmokhtar, O; Azaza, A; Azzouz, A; Benamara, S; Benathmane, T; Benkhedda, S; Bonello, L; Bouzid, A; Hamza, O; Harbi, F; Kara, M; Monsuez, JJ; Paganelli, F; Saidane, M; Seddiki, S; Sik, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aitmokhtar, O | 1 |
| Paganelli, F | 1 |
| Benamara, S | 1 |
| Azaza, A | 1 |
| Bonello, L | 1 |
| Hamza, O | 1 |
| Seddiki, S | 1 |
| Benathmane, T | 1 |
| Saidane, M | 1 |
| Bouzid, A | 1 |
| Kara, M | 1 |
| Sik, A | 1 |
| Azzouz, A | 1 |
| Harbi, F | 1 |
| Monsuez, JJ | 1 |
| Benkhedda, S | 1 |
| Kuliczkowski, W | 1 |
| Gasior, M | 1 |
| Pres, D | 1 |
| Kaczmarski, J | 1 |
| Laszowska, A | 1 |
| Szewczyk, M | 1 |
| Hawranek, M | 1 |
| Tajstra, M | 1 |
| Zeglen, S | 1 |
| Polonski, L | 1 |
| Serebruany, VL | 1 |
| Ren, F | 1 |
| Mu, N | 1 |
| Zhang, X | 1 |
| Tan, J | 1 |
| Li, L | 1 |
| Zhang, C | 1 |
| Dong, M | 1 |
| Riml, S | 1 |
| Wallner, H | 1 |
| Kompatscher, P | 1 |
4 other studies available for aspirin and No-Reflow Phenomenon
| Article | Year |
|---|---|
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Ang | 2017 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf | 2015 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos | 2016 |
Friend or foe? Discussion about dual platelet inhibition as a salvage procedure from imminent flap failure.
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mamma | 2013 |